DiaMedica Advances Preeclampsia and Stroke Trials as Cash Runway Extends to Mid-2027 — DiaMedica Therapeutics Inc.

Event summary

DiaMedica reported $59.9M in cash and short-term investments as of December 31, 2025, up from $44.1M a year earlier.
The company's ReMEDy2 acute ischemic stroke trial is 70% enrolled, with interim analysis expected in the second half of 2026.
DiaMedica plans to initiate a Phase 2 study for early-onset preeclampsia in Q2 2026, following Health Canada's 'No Objection Letter'.
R&D expenses rose to $24.6M in 2025 from $19.1M in 2024, driven by clinical trial expansions.

The big picture

DiaMedica's progress in its preeclampsia and acute ischemic stroke programs comes as the biopharmaceutical industry faces increasing pressure to demonstrate clinical efficacy in high-unmet-need indications. The company's ability to secure regulatory approvals and maintain its cash position will be critical as it competes with larger players in the vascular disease space.

What we're watching

Clinical Momentum: Whether DiaMedica can maintain its enrollment pace in the ReMEDy2 trial and successfully initiate its preeclampsia Phase 2 study.
Regulatory Pathway: The outcome of DiaMedica's discussions with the FDA on alternate species for its preeclampsia trial, expected next quarter.
Financial Flexibility: How long DiaMedica can extend its cash runway beyond mid-2027 through potential additional funding rounds or cost optimizations.